Evidence map›Paper›PMID 40166851›Full record

ReviewAlimentary pharmacology & therapeutics2025

Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression.

Peter J Kahrilas, Laurie Keefer, Rena Yadlapati, Foteini Anastasiou, Joel J Heidelbaugh, Colin W Howden, Juan M Mendive, Edoardo Vincenzo Savarino, Mihaela Udrescu, A Pali S Hungin

Abstract readReview
In one paragraph

Review in Alimentary pharmacology & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Beyond PPIs: New Options for Treating GERD.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peter J KahrilasNorthwestern University, Chicago, Illinois, USA.
Laurie KeeferIcahn School of Medicine at Mount Sinai, New York, New York State, USA.
Rena YadlapatiUniversity of California San Diego, La Jolla, California, USA.
Foteini Anastasiou4th Local Health Team (TOMY), Municipality Practice, Academic Practice of Heraklion, Heraklion, Greece.
Joel J HeidelbaughDepartment of Family Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Colin W HowdenUniversity of Tennessee College of Medicine, Memphis, Tennessee, USA.
Juan M MendiveLa Mina Primary Health Care Academic Centre, Catalan Institute of Health (ICS), University of Barcelona, Barcelona, Spain.
Edoardo Vincenzo SavarinoGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Mihaela UdrescuIndividual Family Practice, Bucharest, Romania.
A Pali S HunginEmeritus Professor of General Practice, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID https://orcid.org/0000-0001-7275-8927

Funding

The MVP Trial: A Randomized Controlled Trial of Mechanism Guided vs PPI Strategy for Laryngopharyngeal RefluxR01DK139089 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Rena Hiren Yadlapati · 2024 to 2026
$2.0M
Mechanism Guided Therapy for Laryngopharyngeal RefluxK23DK125266 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YADLAPATI, RENA HIREN · 2021 to 2025
$963k
NIDDK NIH HHS K23 DK125266NIDDK NIH HHS R01 DK139089
6 · The paper itself

Abstract

backgroundReflux-like symptoms and reflux oesophagitis are often perceived as having the same acid-related aetiology and responsiveness to antisecretory therapy. However, the frequency of residual symptom reporting on proton pump inhibitor (PPI) therapy suggests the two entities have some differential pathophysiological determinants requiring distinct management approaches.

aimsTo examine the complexities of reflux-like symptom pathophysiology and strategies that may be used to target contributing factors beyond acid reflux.

methodsA panel of ten expert clinicians (primary care, gastroenterology and psychology) held a series of online meetings to share perspectives on the underlying contributors to, and management of, reflux-like symptoms when PPIs are ineffective or provide partial relief. This review summarises the agreed key themes that emerged from the expert discussions.

resultsWhile degradation of the anti-reflux barrier dominates in reflux oesophagitis, cognitive-affective, behavioural, and other psychosocial factors can play a major role in symptom persistence. These require individualised management strategies, beginning with education on the gut-brain connection and expectation setting with regard to PPI therapy. A detailed clinical history and patient-reported outcome tools that measure symptom burden and associated anxiety/hypervigilance can help guide management using brain-gut behavioural therapies, supported diet/lifestyle modification, diaphragmatic breathing, weight loss, and/or on-demand symptom control measures according to a patient's specific needs.

conclusionsA paradigm shift in reflux-like symptom management is required such that acid suppression is viewed as one of several interventions that can be utilised as part of a phenotype-driven, individualised approach to care that acknowledges the multiple contributors to symptom burden.

Indexed as

Esophagitis, PepticGastroesophageal RefluxProton Pump InhibitorsHumansPrecision MedicineProton Pump Inhibitorsbrain‐gutmanagementoesophagusrefluxsymptomsthroat

Identifiers

PMID40166851
PMCPMC11981552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.